A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy

3Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Tisagenlecleucel is associated with remarkable outcomes in treating patients up to the age of 25 years with refractory B-cell acute lymphoblastic leukemia (ALL). Yet, due to unique and potentially life-threatening complications, access remains limited to higher-resource and certified centers. Reports of inequity and related disparities in care are emerging. In this multicenter study of ALL patients admitted for anti-leukemia therapy, who required pediatric intensive care (ICU) support (n = 205), patients receiving tisagenlecleucel (n = 39) were compared to those receiving conventional chemotherapy (n = 166). The median time to ICU transfer was 6 (0–43) versus 1 (0–116) days, respectively (p < 0.0001). There was no difference in the use of vasopressor, ionotropic, sedating, and/or paralytic agents between groups, but use of dexamethasone was higher among tisagenlecleucel patients. Patients receiving tisagenlecleucel were more likely to have cardiorespiratory toxicity (p = 0.0002), but there were no differences in diagnostic interventions between both groups and/or differences in ICU length of stay and/or overall hospital survival. Toxicities associated with tisagenlecleucel are generally reversible, and our findings suggest that resource utilization once admitted to the ICU may be similar among patients with ALL receiving tisagenlecleucel versus conventional chemotherapy. As centers consider improved access to care and the feasibility of tisagenlecleucel certification, our study may inform strategic planning.

References Powered by Scopus

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

4070Citations
N/AReaders
Get full text

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

2161Citations
N/AReaders
Get full text

Adaptation and validation of a pediatric sequential organ failure assessment score and evaluation of the Sepsis-3 definitions in critically ill children

437Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study

5Citations
N/AReaders
Get full text

Evolving strategies for addressing CAR T-cell toxicities

1Citations
N/AReaders
Get full text

Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ragoonanan, D., Bhar, S., Mohan, G., Beltramo, F., Khazal, S. J., Hurley, C., … Mahadeo, K. M. (2022). A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1022901

Readers' Seniority

Tooltip

Researcher 4

80%

PhD / Post grad / Masters / Doc 1

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

50%

Nursing and Health Professions 1

17%

Pharmacology, Toxicology and Pharmaceut... 1

17%

Neuroscience 1

17%

Save time finding and organizing research with Mendeley

Sign up for free